Table 1. Characteristics of study participants according to the estimated 10-year absolute risk for CAD incidence and the category for LDL-C management proposed by JAS Guidelines 2017.
| Males | Females | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Total | Estimated 10-year absolute risk for CAD incidence | Management classification | Total | Estimated 10-year absolute risk for CAD incidence | Management classification | |||||
| Low risk | Middle risk | High risk | Category III | Low risk | Middle risk | High risk | Category III | |||
| ＜2% | 2 ≤ risk ＜ 9% | 9% ≤ | DM, CKD,or PAD | ＜2% | 2 ≤ risk ＜ 9% | 9% ≤ | DM, CKD,or PAD | |||
| Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | Mean±SD | |
| Number of participants, n | 909 | 117 | 360 | 68 | 364 | 1,063 | 392 | 290 | 7 | 374 |
| Age, y | 64.6±7.1 | 55.7±8.8 | 64.9±6.0 | 68.9±4.1 | 66.3±5.6 | 64.8±6.7 | 61.4±7.5 | 67.5±4.4 | 69.3±2.6 | 66.2±5.8 |
| Body mass index, kg/m 2 | 23.9±3.0 | 23.4±3.0 | 23.4±2.6 | 23.9±2.6 | 24.5±3.3 | 23.1±3.5 | 22.4±3.3 | 23.4±3.5 | 25.5±4.6 | 23.6±3.6 |
| Systolic blood pressure, mmHg | 132±16 | 120±12 | 131±14 | 147±19 | 135±16 | 127±18 | 118±13 | 137±15 | 160±12 | 129±19 |
| Diastolic blood pressure, mmHg | 80±10 | 75±8 | 81±10 | 86±10 | 80±9 | 74±10 | 70±9 | 77±9 | 86±3 | 75±10 |
| Medication for hypertension, % | 41.1 | 17.9 | 36.4 | 44.1 | 52.7 | 33.7 | 19.4 | 40.0 | 14.3 | 44.1 |
| Total cholesterol, mg/dL | 194±30 | 191±29 | 196±27 | 210±29 | 190±31 | 208±30 | 201±29 | 215±29 | 234±26 | 209±30 |
| HDL-cholesterol, mg/dL | 63±17 | 67±19 | 66±17 | 61±15 | 60±16 | 73±17 | 75±16 | 72±16 | 62±20 | 71±17 |
| Triglycerides, mg/dL | 117±63 | 110±64 | 111±60 | 110±51 | 126±68 | 93±43 | 84±39 | 96±44 | 114±47 | 100±43 |
| LDL-cholesterol, mg/dL | 107±28 | 101±27 | 109±26 | 127±25 | 104±29 | 117±28 | 109±26 | 124±28 | 149±23 | 118±28 |
| Medication for dyslipidaemias, % | 18.5 | 12.0 | 12.2 | 11.8 | 28.0 | 29.6 | 20.9 | 29.3 | 0 | 39.6 |
| HbA1c (NGSP), % | 5.8±0.7 | 5.5±0.2 | 5.6±0.3 | 5.7±0.3 | 6.2±0.9 | 5.7±0.4 | 5.6±0.3 | 5.7±0.3 | 6.0±0.2 | 5.9±0.6 |
| Medication for diabetes mellitus, % | 13.9 | - | - | - | - | 4.3 | - | - | - | - |
| Creatinine, mg/dL | 0.9±0.2 | 0.8±0.1 | 0.8±0.1 | 0.8±0.1 | 1.0±0.2 | 0.7±0.1 | 0.6±0.1 | 0.6±0.1 | 0.6±0.0 | 0.8±0.1 |
| eGFR, mL/min/1.73 m 2 | 69±12 | 76±11 | 73±10 | 71±8 | 62±13 | 67±12 | 73±10 | 71±10 | 71±6 | 57±10 |
| Current smoker, % | 18.0 | 16.2 | 18.3 | 22.1 | 17.6 | 1.8 | 2.8 | 2.4 | 0 | 0.3 |
| Current drinker, % | 74.3 | 76.1 | 76.7 | 69.1 | 72.3 | 23.2 | 29.1 | 22.4 | 42.9 | 17.4 |